Impact of weight loss on fat tissue signaling in muscles
Effect of Weight Loss on Intermuscular Adipose Tissue (IMAT) Signaling
This study is testing how losing weight affects fat tissue in muscles and whether it helps people with obesity improve their insulin sensitivity.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 70 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | University of Colorado, Denver Academic / other |
| Locations | 1 site (Aurora, Colorado) |
| Trial ID | NCT06129110 on ClinicalTrials.gov |
What this trial studies
This intervention focuses on understanding how weight loss affects the molecular signaling of intermuscular adipose tissue (IMAT) in individuals with obesity. Participants will undergo a 12-week dietary intervention aimed at weight loss, with assessments including body composition, blood tests, strength testing, and thigh muscle biopsies before and after the intervention. The study aims to determine how inflammatory molecules from IMAT contribute to muscle insulin resistance and how these molecules change following weight loss. Outcomes will be compared between those who successfully lose weight and those who do not.
Who should consider this trial
Good fit: Ideal candidates are generally healthy men and women aged 18-70 with a BMI between 30-40 who engage in less than 1 hour of exercise per week.
Not a fit: Patients with Type 1 or Type 2 diabetes, thyroid disease, or those currently undergoing menopause may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved strategies for managing obesity-related insulin resistance and muscle weakness.
How similar studies have performed: Other studies have shown promising results in understanding the relationship between weight loss and metabolic health, making this approach both relevant and potentially impactful.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Generally healthy men and women aged 18-70 * BMI between 30-40 * Less than 1 hour of exercise per week * Women: 1. may be pre or post menopausal Exclusion Criteria: * Type 1 or Type 2 diabetes * Thyroid disease * History of lung disease * Active use of nicotine * Severe plasma lipid disorders * Taking hormone replacement drugs, blood thinners, or thiazoladinediones * Women: 1. Currently going through menopause or peri-menopause 2. Pregnant or breastfeeding 3. History of Polycystic Ovary Syndrome
Where this trial is running
Aurora, Colorado
- University of Colorado Anschutz — Aurora, Colorado, United States (Recruiting)
Study contacts
- Study coordinator: Bryan Bergman, PhD
- Email: bryan.bergman@cuanschutz.edu
- Phone: 3037243919
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.